Clinical effectiveness and safety of Camrelizumab immunotherapy in treating advanced esophageal carcinoma.

Abstract

Objective: To analyze the clinical effectiveness and safety of Camrelizumab immunotherapy in patients with advanced esophageal carcinoma (aEC).

Methods: A retrospective study was conducted on 142 aEC cases admitted between May 2020 to October 2022. The patients who received albumin-bound paclitaxel (ALB-bound PTX) and cis-platinum (DDP) were grouped into the control group (n=72), and the others received Camrelizumab immunotherapy in combination with ALB-bound PTX and DDP were grouped in to the research group (n=72). The clinical effectiveness, side effects (rash, nausea/vomiting, impaired liver function, leukopenia, thrombocytopenia, and alopecia), tumor marker levels (CEA, CA199, and CA125), immunoglobulin levels (IGA, IGM, and IGG), immune molecule levels (PD-1 and PD-L1), and the one-year survival rate were compared between the two groups. Furthermore, the risk factors affecting therapeutic effectiveness were identified by binary Logistic regression analysis.

Results: Compared to the control group, the research group demonstrated a higher overall response rate, fewer side effects, and greater reductions in the levels of CEA, CA199, and CA125 after treatment. IgA, IgM, and IgG levels increased significantly in both groups after treatment, with a more pronounced improvement in the research group. PD-1 and PD-L1 levels decreased significantly after treatment, especially in the research group. The one-year survival rate was higher in the research group. Furthermore, treatment modality was a risk factor affecting therapeutic effectiveness in aEC patients.

Conclusions: Camrelizumab immunotherapy is highly effective in treating aEC. It can increase the one-year survival rate, and elevate the levels of immunoglobulins and immune molecules while reducing the levels of tumor markers and incidence of side effects.